Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,626 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- OncoTree
- BREAST
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01530373 | Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients | recruiting | Phase 2 | 110 | University of ArkansasOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | recruiting | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT01788839 | Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | recruiting | — | 475 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06318897 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06524895 | Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery | recruiting | N/A | 32 | Albert Einstein College of MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06709651 | Microbiome Immunotherapy Neoadjuvant Assessment(MINA) | recruiting | — | 30 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04703244 | Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer | recruiting | — | 999 | Mayo ClinicOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06806930 | Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | recruiting | Phase 2 | 90 | George Washington UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07252986 | Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence(COMPASS-BC) | recruiting | — | 2,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 37 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05325632 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | recruiting | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT07342283 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer | recruiting | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07443579 | Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography(MammoView) | recruiting | N/A | 400 | Royal College of Surgeons, IrelandOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05505643 | Cryoablation vs Lumpectomy in T1 Breast Cancers(COOL-IT) | recruiting | N/A | 120 | Washington University School of MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05659797 | FES BPET-DBT in Newly Diagnosed Breast Cancer | recruiting | Early Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05721976 | With Love, Grandma ("Con Cariño, Abuelita") Pilot Study | recruiting | N/A | 60 | University of Miami Sylvester Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06099769 | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | recruiting | Phase 2 | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06217874 | Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer | recruiting | — | 2,000 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06694181 | Safe and Explainable AI | recruiting | — | 300,000 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06802757 | Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer(PRISM-TNBC) | recruiting | Phase 2 | 72 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer | recruiting | Phase 3 | 540 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07416630 | Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients | recruiting | N/A | 30 | Institute of Oncology LjubljanaOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05780814 | The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer(COIN) | recruiting | N/A | 250 | Johns Hopkins UniversityOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05974150 | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | recruiting | — | 25 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | recruiting | Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06104371 | Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy(SentiNeo2) | recruiting | — | 459 | Vastra Gotaland RegionOTHER_GOV | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | recruiting | Phase 1 | 80 | ProteinQure Inc.INDUSTRY | 2 | Feb 23, 2026 | clinicaltrials |
| NCT07193394 | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer(H3RAKLES) | recruiting | Phase 2 | 20 | Institut CurieOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04234386 | GammaPod Dose Escalation Radiation for Early Stage Breast Cancer | recruiting | N/A | 50 | University of Maryland, BaltimoreOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06446882 | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer(DEFINITIVE) | recruiting | N/A | 304 | Fundacio Clinic BarcelonaOTHER | 5 | Feb 20, 2026 | clinicaltrials |
| NCT06877949 | FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer(MONITOR-RCT) | recruiting | N/A | 420 | Odense University HospitalOTHER | 3 | Feb 20, 2026 | clinicaltrials |
| NCT07425002 | Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)(PRISM) | recruiting | N/A | 1,600 | Cancer Trials IrelandNETWORK | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03463954 | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | recruiting | N/A | 122 | Novian Health Inc.INDUSTRY | 5 | Feb 19, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07418125 | Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA(GALIA) | recruiting | N/A | 130 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05074290 | Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 74 | University of FloridaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06291064 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 85 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | recruiting | Phase 2 | 74 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06350500 | A Patient Navigation Program for Addressing Disparities in Breast Cancer Care | recruiting | N/A | 126 | Roswell Park Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 5, 2026source: clinicaltrials